Evan Jones, Director, on Dec 05, 2019, sold 5,951 shares in Veracyte (VCYT) for $178,558. Jones, subsequent to the transactions disclosed in the SEC Form...
On Dec 02, 2019, Chief Scientific & Med Officer, Dr Giulia C Kennedy, exercised options/derivative securities for 15,032 shares. A portion of these...
Veracyte (VCYT) said on Tuesday it has acquired an exclusive global license to NanoString's (NSTG) nCounter platform for diagnostic use to expand its...
Veracyte (VCYT) on Tuesday reported a $0.02 loss per share for Q3, down from $0.12 loss per share in the year-ago period, beating Capital IQ estimate of...
| Address | 6000 Shoreline Court South San Francisco, California 94080 |
| Phone | +1.650.243.6300 |
| Number of Employees | 270 |
| Recent SEC Filing | 12/11/2019 4 |
| Chairman & Chief Executive Officer | Bonnie H. Anderson |
| Chief Operating & Financial Officer | Keith Kennedy |
| Chief Scientific & Medical Officer | Giulia C. Kennedy |
| Chief Information Officer | Ashish Kheterpal |
| Price Open | $28.63 |
| Previous Close | $28.63 |
| 52 Week Range | $10.72 - 31.18 |
| Market Capitalization | $1.4 B |
| Shares Outstanding | 48.8 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 02/24/2020 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.19 |
| Beta vs. S&P 500 | N/A |
| Revenue | $92.0 M |
| Net Profit Margin | -7.08% |
| Return on Equity | -5.33% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
